Overview of Dr. Liaw
Dr. Bobby Liaw is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is one of 188 doctors at The Mount Sinai Hospital and one of 122 doctors at Mount Sinai Beth Israel who specialize in Oncology. He also speaks multiple languages, including Chinese (Mandarin). He has more than 20 publications and over 250 citings.
Office
325 W 15th St
New York, NY 10011Fax+1 212-604-6038
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2012 - 2015
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2010 - 2012- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2009 - 2010
State University of New York Downstate Medical Center College of MedicineClass of 2009, MD
Cornell UniversityBS, Biochemistry, 2001 - 2005
Certifications & Licensure
FL State Medical License 2020 - Present
NY State Medical License 2012 - 2025
MA State Medical License 2009 - 2012- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) Start of enrollment: 2017 Jan 13
Publications & Presentations
PubMed
- The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted T...Zakaria Chakrani, Mann Patel, George Mellgard, Stephen McCroskery, Nathaniel Saffran
Clinical Genitourinary Cancer. 2024-12-01 - Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy.George Mellgard, Nathaniel Saffran, Zakaria Chakrani, Stephen McCroskery, Nicole Taylor
American Journal of Clinical Oncology. 2024-10-01 - Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-target...Zakaria Chakrani, George Mellgard, Nathaniel Saffran, Stephen McCroskery, Nicole Taylor
American Journal of Clinical Oncology. 2024-06-01
Journal Articles
- The Role of Ketoconazole in Current Prostate Cancer CareWilliam Oh, Bobby Liaw, Vaibhav Patel, Nature
Press Mentions
What 5 Doctors Are Excited About in Kidney Cancer ResearchSeptember 5th, 2024- Neuroimmunological Adverse Events Associated with Immune Checkpoint Inhibitor: A Retrospective, Pharmacovigilance Study Using FAERS DatabaseJanuary 9th, 2021
FDA Approval for Darolutamide in Prostate CancerAugust 1st, 2019- Join now to see all
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
